Payment overview · 2025
General Payments
$1,143.33
51 reported records · 19 companies
Healthcare provider profile · identity verified
Ossama Labib, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FALL RIVER, MA · NPI 1225033673
Verified facts
What the public records show
CMS Open Payments records show Ossama Labib, M.D. received $1,143.33 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Rexulti, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 392 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 625 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.18 | 21.8% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $145.83 | 12.8% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.33 | 9.1% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $97.03 | 8.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.42 | 7.0% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.45 | 6.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.69 | 5.5% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.54 | 3.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.98 | 3.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.33 | 2.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.36 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.19 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.73 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.53 | 2.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $24.33 | 2.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.30 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.88 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.86 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.37 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,143.33 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $165.57 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $104.33 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $104.27 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $97.03 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.23 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.42 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $75.45 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.55 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $63.60 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $62.69 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $61.86 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| FLULAVAL QUADRIVALENT Normalized: flulaval quadrivalent |
Biological | GlaxoSmithKline, LLC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 392 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 211 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
392 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
211 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
209 | 40 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
625 | 66 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1421 | 226 |
| Trazodone Hcl | Trazodone Hcl | 1150 | 129 |
| Furosemide | Furosemide | 1124 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 937 | 152 |
| Omeprazole | Omeprazole | 864 | 169 |
| Metoprolol Tartrate | Metoprolol Tartrate | 764 | 119 |
| Mirtazapine | Mirtazapine | 705 | 89 |
| Eliquis | Apixaban | 625 | 66 |
| Gabapentin | Gabapentin | 608 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 514 | 80 |
| Simvastatin | Simvastatin | 494 | 85 |
| Lisinopril | Lisinopril | 469 | 104 |
| Farxiga | Dapagliflozin Propanediol | 392 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 82 |
| Donepezil Hcl | Donepezil Hcl | 342 | 34 |
| Metformin Hcl | Metformin Hcl | 334 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 330 | 64 |
| Sertraline Hcl | Sertraline Hcl | 318 | 60 |
| Lorazepam | Lorazepam | 304 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 298 | 64 |
| Potassium Chloride | Potassium Chloride | 269 | 39 |
| Losartan Potassium | Losartan Potassium | 268 | 48 |
| Valsartan | Valsartan | 261 | 53 |
| Nitroglycerin Patch | Nitroglycerin | 258 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 256 | 24 |
| Alprazolam | Alprazolam | 252 | 36 |
| Meloxicam | Meloxicam | 241 | 60 |
| Repaglinide | Repaglinide | 239 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 36 |
| Metformin Hcl Er | Metformin Hcl | 234 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 229 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 60 |
| Xarelto | Rivaroxaban | 220 | 26 |
| Fenofibrate | Fenofibrate | 211 | 49 |
| Finasteride | Finasteride | 211 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 211 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 32 |
| Divalproex Sodium | Divalproex Sodium | 209 | 26 |
| Trulicity | Dulaglutide | 209 | 40 |
| Prednisone | Prednisone | 207 | 131 |
| Diclofenac Sodium | Diclofenac Sodium | 205 | 63 |
| Allopurinol | Allopurinol | 189 | 39 |
| Clonazepam | Clonazepam | 175 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 164 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 162 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 64 |
| Propranolol Hcl | Propranolol Hcl | 161 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 49 |
| Ibuprofen | Ibuprofen | 152 | 55 |
| Oxycodone Hcl | Oxycodone Hcl | 149 | 35 |
| Celecoxib | Celecoxib | 146 | 28 |
| Buspirone Hcl | Buspirone Hcl | 145 | 28 |
| Memantine Hcl | Memantine Hcl | 144 | 12 |
| Carvedilol | Carvedilol | 143 | 31 |
| Montelukast Sodium | Montelukast Sodium | 138 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 137 | 37 |
| Alendronate Sodium | Alendronate Sodium | 133 | 24 |
| Cefuroxime | Cefuroxime Axetil | 132 | 105 |
| Baclofen | Baclofen | 130 | 17 |
| Meclizine Hcl | Meclizine Hcl | 125 | 39 |
| Ozempic | Semaglutide | 123 | 26 |
| Movantik | Naloxegol Oxalate | 122 | 16 |
| Felodipine Er | Felodipine | 117 | 35 |
| Tramadol Hcl | Tramadol Hcl | 117 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 113 | 39 |
| Levetiracetam | Levetiracetam | 113 | 13 |
| Olanzapine | Olanzapine | 113 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 113 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 19 |
| Famotidine | Famotidine | 112 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 112 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 20 |
| Nystatin | Nystatin | 105 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 16 |
| Linzess | Linaclotide | 100 | 29 |
| Bumetanide | Bumetanide | 96 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 91 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 90 | suppressed |
| Atenolol | Atenolol | 87 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 14 |
| Diazepam | Diazepam | 84 | 15 |
| Spironolactone | Spironolactone | 84 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 82 | suppressed |
| Jardiance | Empagliflozin | 82 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 11 |
| Januvia | Sitagliptin Phosphate | 77 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 70 |
| Clonidine Hcl | Clonidine Hcl | 75 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 54 |
| Lovastatin | Lovastatin | 71 | suppressed |
| Nifedipine Er | Nifedipine | 70 | 18 |
| Ranolazine Er | Ranolazine | 68 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 67 | 15 |
| Pregabalin | Pregabalin | 67 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Colchicine | Colchicine | 63 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 61 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | suppressed |
| Methimazole | Methimazole | 60 | suppressed |
| Glipizide | Glipizide | 58 | 16 |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Irbesartan | Irbesartan | 53 | 14 |
| Topiramate | Topiramate | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 19 |
| Nyamyc | Nystatin | 52 | 27 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Sucralfate | Sucralfate | 48 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 46 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 18 |
| Nateglinide | Nateglinide | 44 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Rybelsus | Semaglutide | 42 | suppressed |
| Sulfasalazine | Sulfasalazine | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Dutasteride | Dutasteride | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 29 |
| Levofloxacin | Levofloxacin | 39 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Lactulose | Lactulose | 38 | 14 |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Erythromycin | Erythromycin Base | 36 | 20 |
| Ketoconazole | Ketoconazole | 36 | 11 |
| Risperidone | Risperidone | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 35 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Humalog | Insulin Lispro | 33 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 15 |
| Torsemide | Torsemide | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Metronidazole | Metronidazole | 31 | 20 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 16 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 21 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 13 |
| Primidone | Primidone | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 16 |
| Lagevrio (Eua) | Molnupiravir | 24 | 24 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Naproxen | Naproxen | 22 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 11 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,143.33 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, CREON, FARXIGA, FLULAVAL QUADRIVALENT, GVOKE HYPOPEN, INSPIRE, LINZESS, OTEZLA, Ohtuvayre, Ozempic, PYRUKYND, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, VIVITROL, VOQUEZNA, VYNDAMAX, YUPELRI, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error